BCBS Arizona · Type 2 Diabetes

BCBS Arizona coverage for Mounjaro (Type 2 Diabetes)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

A1C of 6.5% or higher
Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Type 2 Diabetes - Initial Approval

All of:

Diagnosis of Type 2 diabetes as adjunct to diet and exercise to improve glycemic control
Medication is NOT solely being used for weight loss
Age consistent with FDA labeling
Medical regimen includes standard of care for type 2 diabetes
Does not have type 1 diabetes
No severe gastrointestinal disease (gastroparesis)
No personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
No concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
Failure, contraindication, or intolerance with THREE generic equivalents (if available) for at least three months each

Plus any one of:

A1C >= 6.5%
Fasting plasma glucose >= 126 mg/dL
2-hour plasma glucose >= 200 mg/dL during oral glucose tolerance test
Random plasma glucose >= 200 mg/dL

Documentation to bring

Completed prior authorization request form signed by prescribing provider
Chart notes
Lab results confirming T2DM diagnosis (A1C >= 6.5%, fasting plasma glucose >= 126 mg/dL, 2-hour PG >= 200 mg/dL during OGTT, or random plasma glucose >= 200 mg/dL)
Documentation of failure, contraindication, or intolerance to three generic equivalent medications for at least three months each
Supporting clinical documentation confirming standard of care for type 2 diabetes is in place

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for improvement in A1C and Decrease in A1C from baseline; adherence to prescribed therapy regimen for diabetes including diet and exercise.

Not covered when

Severe gastrointestinal disease (gastroparesis)
Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
Medication used solely for weight loss (not covered under this indication)
Type 1 diabetes

Policy note: Policy applies to Commercial and/or Marketplace plans only. Explicitly excludes Federal Employee Program, Medicare Advantage, Medicaid, and out-of-state BCBS plans. Brand-specific step therapy requires failure/contraindication/intolerance to THREE generic equivalents for at least 3 months each. At continuation, pancreatitis, severe hypersensitivity reaction, acute kidney injury, drug-induced immune mediated thrombocytopenia, and acute gallbladder disease are additional safety exclusions. Manufacturer samples and coupons not counted toward continuation eligibility. Member may be referred to case management for diabetes-related ancillary services.

Policy effective April 1, 2026 · verified June 2, 2026 · source: Download

ACA Marketplace